DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/04/19

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q3 GAAP EPS of -$1.28 misses by $0.12 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GIST) - - Clinical Progress Across Pipeline with Data Presentations for Ripretinib, Rebastinib and DCC-3014 ...

Deciphera Pharmaceuticals ( DCPH +5% ) is up on average volume on the heels of updated data from a Phase 1 clinical trial evaluating ripretinib in patients with gastrointestinal stromal tumors (GIST) in 2nd, 3rd and 4th line settings. More news on: Deciphera Pharmaceuticals, Inc., He...

- Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase 1 Study of Ripretinib in Patients Receiving 150 mg QD as Starting Dose - - DCC-3014 Phase 1 Data Demonstrated Tolerability, Pharmacokinetics and Biomar...

October 29, 2019 Palm Beach, FL –October 29, 2019 – Acute myeloid leukemia (AML), is the most common of the four major types of leukemia. Without treatment, AML is often deadly within a few months. Many of the symptoms of the disease are nonspecific and could include sym...

- Combination of Rebastinib and Paclitaxel Exhibited Encouraging Preliminary Anti-tumor Activity Across Treatment Arms in the Ongoing Phase 1b/2 Clinical Study - - DCC-3116 Represents a Differentiated Approach to Autophagy Inhibition and a First-in-Class Opportunity for a New Therapeut...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019. In connection with the earning...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that data from four of the Company’s pipeline programs will be presented in poster sessions at the AACR-NCI-EORTC Internationa...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...